Actively Recruiting
Assessing Signatures for Fibrosis Detection in Chronic Liver Disease: A Step Beyond Conventional Biomarkers
Led by Universitair Ziekenhuis Brussel · Updated on 2026-05-06
110
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying chronic liver disease (CLD), a condition where liver fibrosis, or scarring, disrupts normal liver function. This research focuses on the role of hepatic stellate cells (HSCs) that become activated when liver cells are damaged, leading to fibrosis. Current biomarkers do not effectively measure HSC activation, which may be a more sensitive indicator than fibrosis itself. The study aims to find biomarkers that better reflect the stage of liver fibrosis in a large group of patients with CLD from various causes. Participants will have blood samples taken using EDTA tubes to analyze biomarkers linked to liver fibrosis. The study is interventional and involves collecting blood to correlate biomarker levels with fibrosis stages. This procedure occurs at the beginning of the study, with no mention of additional treatments or study arms. During the study, participants will undergo blood draws and a transient elastography test (Fibroscan4) to assess liver fibrosis. Researchers will monitor the correlation between biomarker levels in blood and the liver fibrosis stage. The main measurement occurs on the first day, and safety and eligibility are closely checked. The study will continue until January 2028, involving adults aged 18 and older with chronic liver disease.
CONDITIONS
Brief Title
Assessing Signatures for Fibrosis Detection in Chronic Liver Disease: A Step Beyond Conventional Biomarkers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Diagnosis of chronic liver disease including alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease, viral hepatitis, autoimmune hepatitis, cholestatic liver disease, or hemochromatosis
You will not qualify if you...
- Younger than 18 years of age
- Diagnosis of acute hepatitis
- Contraindications for transient elastography (Fibroscan4) such as ascites or overt heart failure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo blood draws to assess biomarkers related to liver fibrosis.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
UZ Brussel
Brussels, Belgium, 1090
Actively Recruiting
Research Team
S
Silke François
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here